CXCL9 and neoplasm: The relationship between the CXCL9,10,11/CXCR3 pathways and PD-1/PD-L1 is a vital area of research, and combining this pathway with other immunotherapies improves the efficacy of tumor immunotherapy by enhancing the inhibition of tumor progression through multiple mechanisms.